Bosutinib
Spécifications
380843-75-4Numéro CAS
700-455-1Numéro CE
4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrileNom IUPAC
C26H29Cl2N5O3Formule chimique
530.4 g/molMasse molaire
Bosutinib; 380843-75-4; SKI-606; SKI 606; 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; SK-606; 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile; 5018V4AEZ0; CHEBI:39112; DTXSID10861568; 3-Quinolinecarbonitrile, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-; bosutinibum; uglysycpd2; RefChem:58901; DTXCID40207910; L01XE14; 4-Anilinobenzo(g)quinoline-3-carbonitrile; 700-455-1; 943-866-3; 4-Anilino-3-quinolinecarbonitrile; Bosutinib (SKI-606); BOSULIF; SKI606; 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; Bosutinib (USAN); Bosutinib [USAN]; MFCD07367846; 4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile; BOSUTINIB ISOMER 1; CHEMBL288441; C26H29Cl2N5O3; SKI-606); 4-(2,4-dichloro-5-methoxy-anilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; Bosutinib [USAN:INN]; NCGC00241107-01; UNII-5018V4AEZ0; Bosutinib API; Bosutinib (Standard); Bosutinib,SKI-606; BOSUTINIB [INN]; BOSUTINIB [MI]; BOSUTINIB [VANDF]; PF-5208763; BOSUTINIB [MART.]; EC 700-455-1; BOSUTINIB [WHO-DD]; Bosutinib (SKI-606)?; MLS006011212; SCHEMBL158390; BDBM4552; GTPL5710; orb1225150; orb1310890; orb3141310; Bosutinib Isomer 1, Free Base; Bosutinib, >=98% (HPLC); SCHEMBL29350234; SCHEMBL29428159; EX-A391; UBPYILGKFZZVDX-UHFFFAOYSA-N; GLXC-90178; HMS2043A22; HMS3244A03; HMS3244A04; HMS3244B03; HMS3651C03; HMS3672K11; HMS3743E09; HMS5079M03; K00615a; EBC-11336; HB1323; HY-10158R; NSC765694; NSC799367; SK 606; AKOS015902521; AC-2413; CCG-208129; CS-0118; DB06616; FB19002; NSC-765694; NSC-799367; PB30881; SDCCGSBI-0646926.P001; NCGC00241107-03; NCGC00241107-05; NCGC00241107-06; AS-11064; HY-10158; SMR002530350; NS00002757; S1014; SW220197-1; D03252; AB01565836_03; EN300-7565041; F794031; Q894611; SR-01000941572; SR-01000941572-1; BRD-K99964838-001-01-0; BRD-K99964838-001-06-9; BRD-K99964838-001-11-9; BRD-K99964838-001-12-7; Z2216885221; 3-QUINOLINECARBONITRILE, 4-((2,4-DICHLORO-5-METHOXYPHENYL)AMINO)-6-METHYL-1-PIPERAZINYL)PROPOXY)-; 4-(2,4-Dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)propoxy]quinoline-3-carbonitrileSynonymes
Produits contenant Bosutinib
BOSUTINIB ZENTIVA 500 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB ZENTIVA 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB ZENTIVA 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB STADA 500 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB STADA 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB STADA 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB DR. REDDYS 500 COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB DR. REDDYS 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB DR. REDDYS 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGBOSUTINIB ZENTIVA 500 mg, comprimé pelliculéBOSUTINIB ZENTIVA 400 mg, comprimé pelliculéBOSUTINIB ZENTIVA 100 mg, comprimé pelliculé
Page 1 sur 3
Entreprises vendant Bosutinib
ML
MSN LaboratoriesIndiaRP
Reddy Pharma Iberia S.A.SpainLC
LEAP CHEM CO., LTD.Page 1 sur 2